Table 3. Occurrence of adverse events (n=9).
| Adverse events | N (%) |
|
|---|---|---|
| Grade 1 to 4 | Grade 3 to 4 | |
| Hematologic toxicity | ||
| Leukopenia | 8 (88.9) | 3 (33.3) |
| Neutropenia | 8 (88.9) | 7 (77.8) |
| Anemia | 3 (33.3) | |
| Thrombocytopenia | 1 (11.1) | |
| Non-hematologic toxicity | ||
| Cardiology | ||
| Hypertension | 3 (33.3) | |
| Dermatology | ||
| Hand-foot syndrome | 9 (100.0) | 2 (22.2) |
| Oral ulceration | 1 (11.1) | |
| Oral mucositis | 1 (11.1) | |
| Rash | 1 (11.1) | |
| Infectious disease | ||
| Fever | 2 (22.2) | |
| GI | ||
| Anorexia | 8 (88.9) | |
| Nausea | 6 (66.7) | |
| Vomiting | 3 (33.3) | |
| Constipation | 2 (22.2) | |
| Diarrhea | 2 (22.2) | |
| Liver dysfunction | ||
| ALT increase | 2 (22.2) | 1 (11.1) |
| AST increase | 1 (11.1) | 1 (11.1) |
| GGT increase | 1 (11.1) | 1 (11.1) |
| Billirubin increase | 1 (11.1) | 1 (11.1) |
| Others | ||
| Neurotoxicity | 1 (11.1) | |
| HTG | 1 (11.1) | |
| α-HBDH increase | 1 (11.1) | |
| LDH increase | 1 (11.1) | |
| Alopecia | 1 (11.1) | |
| Fatigue | 1 (11.1) | |
GI, gastrointestinal; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; HTG, hypertriglyceridemia; α-HBDH, α-hydroxybutyrate dehydrogenase; LDH, lactate dehydrogenase.